Obesity Drugs Should Be Covered Under Part D, Drug Firms Urge CMS
Executive Summary
CMS should withdraw its current guidance barring Medicare Part D reimbursement of obesity drugs, the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization advise in separate July 24 comments to the agency